I'm told by colleagues in the life sciences and pharma space that it isn't just "safety" but more like artificial market segmentation. If one has to pay extra for guardrail removal, then that's market segmentation. Anthropic makes most money from company whales. Want the guardrails gone? Pay a lot extra over baseline. But Mythos probably had PEFT adapters, so that at least makes it a bit different. But still there is not nearly enough transparency about these things.
And oopsie whoopsie, looks like we accidentally guardrailed out all of the startups that might challenge your pharmaceutical company. Thanks for being such a loyal customer :)